Martha Gulati, MD, spoke to Cardiovascular Business at AHA Scientific Sessions 2024 about key developments in obesity treatment and CVD prevention.

Abbott expects the new facility to produce more FreeStyle Libre 3 sensors than anywhere else in the world.

Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.

The popular diabetes drug, which can also benefit patients with heart failure and sleep apnea, resulted in an average weight loss of 23%. Once treatment stopped, the effects started to fade rather quickly. 

The new technology, still under development, could help physicians screen patients for diabetes and hypertension with high-speed video recordings. 

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Sanjit S. Jolly, MD, MSc, reviewed his team's late-breaking data on treating heart attack patients with colchicine. "I think inflammation is an important area, but I don't think colchicine is the magic bullet," he said.

Sitting too long can be bad for the heart, but standing desks do not appear to make a difference.